The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This presentation contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company’s ability to successfully commercialize the HEPZATO KIT; the Company’s successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of Delcath and third-party suppliers/manufacturers; the Company’s successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; our ability to obtain reimbursement for commercialized product; the Company’s ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT; the timing and results of the Company’s clinical trials, our determination whether to continue a clinical trial program or to focus on other alternative indications, and the impact of the COVID-19 pandemic or other pandemics on the completion of our clinical trials; the impact of the presentations at major medical conferences and future clinical results consistent with the data presented; uncertainties relating to the timing and results of research and development projects; and uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Executive Summary

Delcath aims to be the leader in targeted, safe and highly-effective minimally-invasive treatments for patients with cancers of the liver.

### UNMET NEED LIVER CANCER
- **Incidence US/EU**
  - >200K primary and metastatic liver tumors per year\(^1-^{14}\)
- **Current local/regional treatments**
  - Cannot treat the whole liver
  - Targeted to visible and accessible tumors
  - Limited in their ability to retreat

### HEPATIC DELIVERY SYSTEM (HDS)
- HDS + Melphalan enables the Percutaneous Hepatic Perfusion (PHP) Procedure
  - Delivers high dose chemotherapy to the entire liver
  - Limits systemic exposure
  - Minimally invasive, repeatable and well-tolerated
- **US:** HEPZATO KIT (Melphalan/HDS)
- **EU:** CHEMOSAT (HDS)

### COMPANY & CLINICAL PROGRAM
- **FDA Approved 8/14/23**
  - Metastatic Ocular Melanoma (mUM)
  - Liver failure #1 cause of death in mUM
  - Response rates >36%
  - 1 Year OS** = 80%
- **Real World Evidence**
  - >1k commercial treatments in EU
  - Multiple single center publications
- **Launch Expected Q4 ‘23**

### LARGE MARKET OPPORTUNITY
- **Near-term (mUM)**
  - Ultra orphan pricing dynamic
  - >$600M TAM in US/EU
- **Longer Term (CRC, ICC, Pancreatic, etc.)**
  - >>$1B TAM
  - Investigator interest in more than 10 other indications

---

* mUM – metastatic Uveal Melanoma, also known as metastatic Ocular Melanoma
** Exploratory endpoint in FOCUS trial
Limitations of Current Liver-Directed Therapies

**Trans Arterial Chemo Embolization (TACE)**
- Beads obstruct blood flow to tumor and elute chemo
- **50-60k treatments** per year in US (and growing)

<table>
<thead>
<tr>
<th>Diffuse disease: cannot be treated with a tumor-by-tumor modality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Many tumors are not imageable – micro-metastases are common</td>
</tr>
</tbody>
</table>

**Y90**
- Radioactive beads delivered into the tumor
- **10-15k treatments per year** in US (and growing)

| Effective, but tumors recur & retreatment limited due to damaged vasculature |

Majority of Treatment

1. Trans Arterial Chemo Embolization (TACE)
2. Y90
HEPZATO KIT™: Enables Percutaneous Hepatic Perfusion (PHP)
Repeatable, safe & effective liver-focused disease control

**ISOLATION**
Hepatic venous flow is isolated, enabling 12x increased dose

**SATURATION**
Melphalan (chemo) treats micro and macro lesions simultaneously

**Filtration**
Proprietary filters remove greater than 85% of chemo from the body

Liver-Dominant Cancers

High incidence with poor prognosis

Many patients with liver metastases are not amenable to surgical resection largely due to extensive tumor burden\(^\text{17}\).

Liver: Common Site of Metastases

Limited Effective Systemic Treatments

- Systemic therapies - low efficacy
- Immuno-oncology agents - become less effective in the presence of metastases

Limited Overall Survival – Unresectable Liver Cancer

- Often the life-limiting organ

US Incidence of Liver Dominant Cancers*

(partial set shown)

**Metastatic Ocular Melanoma (mOM)\(^{16,4}\), Cholangiocarcinoma (ICC)\(^{4,5}\), Liver-dominant Breast Cancer (mBC)\(^{12}\), Metastatic Neuroendocrine Tumors (mNET)\(^{13,18}\), Metastatic Pancreatic Cancer (mPC)\(^{13,15}\), Metastatic Colorectal Cancer (mCRC)\(^{13,14}\), Hepatocellular carcinoma (HCC)\(^{17}\)**
mUM: Beachhead Market Opportunity
High Unmet Need, Favorable Reimbursement Environment

Unmet Need
- >5,000 cases of primary ocular melanoma per year in the US/EU \(^{18}\)
- ~50% metastasize to the liver \(^{4,19}\)
- US TAM ~800 patients, Europe ~1,200 patients
- Median survival up to 12 months \(^{20}\)
- 55% of patients have no approved treatment option, most patients treated with multiple lines of therapy

Low Risk Commercial Opportunity
- FDA Approved 8/14/23
- Commercial launch 4Q '23
- Commercial team led by TheraSphere (BSX) veterans
- Focused commercial effort: 20 US treatment centers @ 2 patients/week = ~70% TAM

High Barrier to Entry
- Orphan indication status allows for extended exclusivity
- HEPZATO is a combination drug device regulated by CDER – no traditional ANDA pathway
- IP around HEPZATO limits any 505(b)(2) follow-on

Favorable US Commercial Economics
- Favorable US reimbursement environment for ultra orphan outpatient MD administered drugs
- KIMMTRAK® (tebentafusp-tebn) (approved 1Q '22 for ~45% of mUM population) priced at an average of $790K per patient, reported $41.7M in 2Q '23
Patient Journey (Pre-Metastatic)

~2,000 patients

Initial screening

- Ophthalmology Optometrists
- Eye specialist

Initial diagnosis & treatment

- Enucleation
- Radiation
- Photodynamic therapy

Screening frequency dependent on risk level

- Higher risk patients (50%) are screened at a high frequency
- Lower risk patients (50%) are screened at a lower frequency

Medical Oncologist

Surveillance frequency

~3-5 YEARS

~1,000 patients

Surveillance at Academic Center

Surveillance by Ophthalmologist/Ocular Oncologist

Surveillance at Nonacademic Center

Milestone: Surveillance decision made

Gene expression profiling may occur here
Patient Journey (Post Metastatic)

Milestone: Metastases detected

Treatment Decision

Liver-directed therapy

Surgical resection

Surgical oncologist

Interventional radiologist

Systemic therapy

Medical oncologist

Most patients receive both systemic and liver-directed therapies

~1000 patients

HEPZATO TAM: ~800 patients
Liver metastases: a significant clinical problem in mUM

Half of all patients with UM develop systemic metastases\textsuperscript{21,22}

- The liver is involved in 90\% of cases of metastatic disease\textsuperscript{21,22}
- In 50\% of mUM patients, the liver is the only site of metastasis\textsuperscript{21,22}
- Most patients with mUM die from liver failure\textsuperscript{22}
- 1-year OS rate of patients with metastatic disease in the liver is 13\%; mOS with median survival ranging from 4 to 15 months\textsuperscript{24,25}

mUM patients have micrometastases with or without the presence of radiologically visible metastases\textsuperscript{23}

Liver directed treatment, such as Isolated Hepatic Infusion* (IHP), achieves better efficacy (ORR, PFS, PFS) compared to systemic therapy\textsuperscript{26}

IHP is an invasive surgical technique for delivering high doses of chemotherapy to the liver; procedure related mortality and morbidity prevented common usage. PHP is a minimally invasive, safer procedure which accomplishes the same goals as IHP and can be performed up to 6 times.
Diffuse/Miliary Metastatic Pattern in mUM

Diffuse disease is difficult to treat with current options

- Solitary liver lesions are often treated with surgery or ablation
- Radiographically metastatic Uveal Melanoma can initially present only as focal lesions
- As is often the case, the true nature of the disease may only be seen upon visual confirmation
- Traditional liver directed therapy mechanism of action is not ideal if a whole liver treatment is needed
- Whole organ therapy delivers medication to a specific organ or tissue through its blood supply, then filters out the medication to minimize systemic exposure

* Data on File
Estimated 80%+ of mUM Patients Are Eligible

1 INDICATIONS AND USAGE
HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Indicated Patient Population includes

- Treatment naïve and previously treated patients
- No HLA genotype restrictions
Box Warnings Managed By REMS

Risk Evaluation and Mitigation Strategy Program = Training & Monitoring

WARNING: PERI-PROCEDURAL COMPLICATIONS, MYELOSUPPRESSION

- Severe peri-procedural complications including hemorrhage, hepatocellular injury, and thromboembolic events may occur via hepatic intra-arterial administration of HEPZATO. Assess patients for these adverse reactions during and for at least 72 hours following administration of HEPZATO [see Warnings and Precautions (5.1)].
- HEPZATO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the HEPZATO KIT REMS [see Warnings and Precautions (5.2)].
- Myelosuppression with resulting severe infection, bleeding, or symptomatic anemia may occur with HEPZATO. Monitor hematologic laboratory parameters and delay additional cycles of HEPZATO therapy until blood counts have improved. [see Warnings and Precautions (5.3)]

European experience has shown that the procedure can be safely conducted by Interventional Radiology team after appropriate training.

REMS program goals are to standardize training, ensure consistent treatment methodology and monitor outcomes.

Myelosuppression is a black box warning for generic melphalan, the management of which is standard practice for oncologists.
FOCUS Trial

Registration Clinical Trial for Patients with mUM

• Multinational, multicenter, single-arm trial

• Efficacy Endpoints:
  » Primary: Objective Response Rate (ORR) compared to meta-analysis of IO therapy
  » Secondary: Duration of Response (DOR), Disease Control Rate (DCR), Overall Survival (OS), Progression Free Survival (PFS)

• 102 patients enrolled, 91 completed treatments at 23 centers in the US and EU

• HEPZATO Tx every 6-8 weeks up to a maximum of 6 cycles
FOCUS Trial
Single Arm Trial Efficacy Data in PI

<table>
<thead>
<tr>
<th>Efficacy Endpoint</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR, n (%)</td>
<td>33 (36.3)</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[26.44, 47.01]</td>
</tr>
<tr>
<td>Median DOR, months</td>
<td>14</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[8.31-17.74]</td>
</tr>
<tr>
<td>DCR, n (%)</td>
<td>67 (73.6)</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[63.35, 82.31]</td>
</tr>
</tbody>
</table>

- 91 treated patients
- Trial powered to show an ORR advantage over a meta-analysis of Best Alternative Care (checkpoint inhibitors, chemotherapy, other liver directed therapy)
- Lower bound of FOCUS ORR (26.4) is significantly higher than the upper bound of the meta-analysis (8.3%)
- Prescribing Information includes ORR, DOR and response categories
- Full analysis with final data cut pending publication – manuscript in process
HEPZATO Response Predicts Survival

Exploratory Analyses*

<table>
<thead>
<tr>
<th></th>
<th>CR (N=7)</th>
<th>PR (N=26)</th>
<th>SD (N=34)</th>
<th>PD/ND (N=24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Status of OS, N (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Events</td>
<td>1 (14.3)</td>
<td>17 (65.4)</td>
<td>29 (85.3)</td>
<td>20 (83.3)</td>
</tr>
<tr>
<td>Censored</td>
<td>6 (85.7)</td>
<td>9 (34.6)</td>
<td>5 (14.7)</td>
<td>4 (16.7)</td>
</tr>
<tr>
<td>Median OS (Months)†</td>
<td>NC</td>
<td>28.16</td>
<td>19.25</td>
<td>11.99</td>
</tr>
<tr>
<td>95% CI</td>
<td>[26.71, NC]</td>
<td>[23.46, 34.46]</td>
<td>[15.90, 23.00]</td>
<td>[8.18, 14.03]</td>
</tr>
<tr>
<td>p-value‡</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CR=complete response, PR=partial response, SD=stable disease, PD=progressive disease, ND=not done, BOR=best overall response
Note: NC = Not calculable, due to the number of events within the stratum (n=1)
† Kaplan-Meier estimates.
‡ Log-Rank test.
* 02-Dec-2022 data cut, patients followed through May, 2023

Analysis Supports that ORR is Clinically Meaningful
OS and PFS Trend Favorable Relative to Historical Results

Pre-Specified Exploratory Analyses*

<table>
<thead>
<tr>
<th>Secondary Endpoint</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median OS, months</td>
<td>20.53</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[16.79, 25.26]</td>
</tr>
<tr>
<td>1 Year OS, K-M Probability Point Estimate</td>
<td>0.80</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[0.70, 0.87]</td>
</tr>
<tr>
<td>Median PFS, Months</td>
<td>9.03</td>
</tr>
<tr>
<td>[95% CI]</td>
<td>[6.34, 11.56]</td>
</tr>
</tbody>
</table>

* 02-Dec-2022 data cut, patients followed through May, 2023
## Published mUM Prospective and Retrospective Studies*

<table>
<thead>
<tr>
<th>Clinical Study/Publication</th>
<th>Study Type</th>
<th>Treatment</th>
<th>N</th>
<th>Median OS (months)</th>
<th>1 year OS</th>
<th>Median PFS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOCUS</td>
<td>Single-Arm</td>
<td>Hepzato</td>
<td>91&lt;sup&gt;AL&lt;/sup&gt;</td>
<td>20.53</td>
<td>80%</td>
<td>9.03</td>
</tr>
<tr>
<td>Khoja et al 2019&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Meta-Analysis</td>
<td>systemic and liver-directed therapies</td>
<td>912</td>
<td>10.2</td>
<td>NA</td>
<td>3.3</td>
</tr>
<tr>
<td>Rantala et al 2019&lt;sup&gt;34&lt;/sup&gt;</td>
<td>Meta-Analysis</td>
<td>systemic and liver-directed therapies</td>
<td>2,494</td>
<td>12.84</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Piulats et al 2021&lt;sup&gt;35&lt;/sup&gt;</td>
<td>Single-Arm</td>
<td>ipi plus nivo</td>
<td>52&lt;sup&gt;TN&lt;/sup&gt;</td>
<td>12.7</td>
<td>NA</td>
<td>3.0</td>
</tr>
<tr>
<td>Heppt et al 2019&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Single-Arm</td>
<td>ipi plus (pembro or nivo)</td>
<td>64&lt;sup&gt;AL&lt;/sup&gt;</td>
<td>16.1</td>
<td>NA</td>
<td>3.0</td>
</tr>
<tr>
<td>Nathan et al 2021&lt;sup&gt;37&lt;/sup&gt;</td>
<td>Randomized</td>
<td>tebentafusp</td>
<td>252&lt;sup&gt;TN&lt;/sup&gt;</td>
<td>21.7</td>
<td>73%</td>
<td>3.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>control</td>
<td>126&lt;sup&gt;TN&lt;/sup&gt;</td>
<td>16</td>
<td>59%</td>
<td>2.9</td>
</tr>
</tbody>
</table>

TN = Treatment Naïve, AL = Any Line
*Studies from 2019 or later with >50 patients

Ipi = ipilimumab, nivo = nivolumab, pembro = pembrolizumab
<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>Primarily Hematological</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Adverse Reactions</td>
<td>N=95</td>
</tr>
<tr>
<td></td>
<td>All Grades (%)</td>
</tr>
<tr>
<td>Hypotension</td>
<td>13</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>23</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>39</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>17</td>
</tr>
<tr>
<td>Musculoskeletal Pain</td>
<td>46</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>15</td>
</tr>
<tr>
<td>Nausea</td>
<td>57</td>
</tr>
<tr>
<td>Vomiting</td>
<td>35</td>
</tr>
<tr>
<td>Fatigue</td>
<td>65</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>16</td>
</tr>
<tr>
<td>Groin Pain</td>
<td>11</td>
</tr>
<tr>
<td>Cough</td>
<td>15</td>
</tr>
<tr>
<td>Headache</td>
<td>19</td>
</tr>
<tr>
<td>Lethargy</td>
<td>12</td>
</tr>
<tr>
<td>Dizziness</td>
<td>11</td>
</tr>
<tr>
<td>Contusion</td>
<td>17</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>16</td>
</tr>
</tbody>
</table>

Most hematological side effects result from melphalan

Side effect profile similar to other cytotoxics commonly Used By Oncologists
Patients Referred to Multidisciplinary Treatment Teams

Oncologists Are Generally the Decision Makers
Training Key to Expanding Number of Treating Sites and Capacity

Multidisciplinary Teams to Be Expanded To Increase Both Training Capacity and Patient Flow

Today

Expand Treatment Teams
Increase # HCP Trainers & Treatment Capacity

Increase # Sites

Expanded Treatment Capacity
Plan To Launch at 10 Treating Sites
Leveraging EAP and Longitudinal Data to Build Referral Networks

---

**EAP – Currently 3 Sites**
- Provide immediate access to patients
- First Commercial Sites
- Train new medical teams to use Hepzato after launch

---

**Leverage Longitudinal Data**
- Partnered with data provider to access patient level longitudinal data with 3-week refresh
- Accurately map and quantify surveillance, referral and treatment patterns at the patient and MD level
# Treating Centers – Current Targets for Launch

<table>
<thead>
<tr>
<th>Institution</th>
<th>City</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moffitt Cancer Center</td>
<td>Tampa, Florida</td>
<td>EAP - Open and Enrolling</td>
</tr>
<tr>
<td>Duke University</td>
<td>Durham, North Carolina</td>
<td>EAP - Open and Enrolling</td>
</tr>
<tr>
<td>University of Tennessee</td>
<td>Memphis, Tennessee</td>
<td>EAP - Open and Enrolling</td>
</tr>
<tr>
<td>Stanford University</td>
<td>Stanford, California</td>
<td>EAP - Plans to join</td>
</tr>
<tr>
<td>Ohio State University</td>
<td>Columbus, Ohio</td>
<td>EAP - Plans to join</td>
</tr>
<tr>
<td>Mayo Clinic Hospital</td>
<td>Jacksonville, Florida</td>
<td>EAP - Plans to join</td>
</tr>
<tr>
<td>HonorHealth</td>
<td>Scottsdale, Arizona</td>
<td>Confirmed interest in being a treating center</td>
</tr>
<tr>
<td>Thomas Jefferson University</td>
<td>Philadelphia, Pennsylvania</td>
<td>Confirmed interest in being a treating center</td>
</tr>
<tr>
<td>University of Miami</td>
<td>Miami, Florida</td>
<td>Confirmed interest in being a treating center</td>
</tr>
</tbody>
</table>
Specialized, Targeted Sales Team

Two Complementary Teams of Representatives

**Hospital Representative**

Responsibilities

- Manage Treating Centers Including VAC/Formulary
- Support Treating Teams
- Facilitate REMS Compliance
- Generate Intra-Center Referrals
- Prospect and Open New Centers with Oncology Representative

**Oncology Representative**

Responsibilities

- Generate Inter-Center Referrals
- Support Hospital Rep / Generate Intra-Center Referrals
- Prospect and Open New Centers with Hospital Representative
Reimbursement

HEPZATO will be billed as a drug with a J-Code

**Medicare Patients**
- Initially a C-Code
- Majority of patients will be outpatient (2 midnight rule) with the drug directly covered by Medicare

**Private Payer Patients**
- Private Payers for rare disease generally follow Medicare guidelines and we expect these patients to be treated as outpatients
- Prior-Authorization of patients might be needed, we are planning to contract out a hub service
- Centers of Excellence (Prospective Payment System (PPS) exempt and NCI designated Cancer Centers) have the leverage to negotiate favorable rates and reimbursement terms (our target sites are all either PPS exempt or NCI Cancer Centers)
PHP Is ALREADY Part of Current NCCN Guidelines for mUM

Regional Isolation Perfusion

Methods include isolated hepatic infusion (IHP), percutaneous hepatic perfusion (PHP), HAI, and embolization techniques. PHP is a simpler, less invasive alternative to IHP that can be repeated. It uses a double-balloon catheter inserted into the inferior vena cava to isolate hepatic venous blood that is then filtered extracorporeally.
Components of Hospital Reimbursement

Assuming Outpatient Pass Through Status with C Code

Drugs
- ASP+6% (CMS)
- Likely similar for commercial payers

Healthcare Facility Fee
- Highly variable based on coding – we do not “map” to any existing code
- Using existing codes is advised and should provide the hospital adequate payment

“Physician” payment
- Actually goes to hospital but still matters to MD
- Highly variable based on coding – we do not “map” to any existing code
- Using existing codes is advised and should provide the hospital adequate payment

CPT Code mapping complete – while important, it will not have a meaningful impact on drug pricing decision
### HEPZATO Pricing Consistent with Other Approved Therapy

#### At First Assessment (first time to discontinue treatment because of progression)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose Cost*</th>
<th>Treatments #</th>
<th>Total cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kimmtrak</td>
<td>$19,289</td>
<td>24</td>
<td>$462,936</td>
</tr>
<tr>
<td>Hepzato</td>
<td>$182,500</td>
<td>2</td>
<td>$365,000</td>
</tr>
</tbody>
</table>

#### Mean Hepzato treatment vs. mean treatment duration of Kimmtrak (per pivotal trials)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose Cost</th>
<th>Mean Treatments #</th>
<th>Total cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kimmtrak</td>
<td>$19,289</td>
<td>41</td>
<td>$790,849</td>
</tr>
<tr>
<td>Hepzato</td>
<td>$182,500</td>
<td>4.1</td>
<td>$748,250</td>
</tr>
</tbody>
</table>

#### Maximum Hepzato treatment vs. Annual treatment duration of Kimmtrak

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose Cost</th>
<th>Max / Annual Treatments #</th>
<th>Total cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kimmtrak</td>
<td>$19,289</td>
<td>52</td>
<td>$1,003,028</td>
</tr>
<tr>
<td>Hepzato</td>
<td>$182,500</td>
<td>6</td>
<td>$1,095,000</td>
</tr>
</tbody>
</table>

*Dose Cost ASP calculated using 7/2023 CMS payment allowance limit*
Rapid Uptake for FDA Approved Treatment in mUM

**Demonstrated demand for FDA approved treatments for mUM**
- KIMMTRAK - $41.7 million in Q2 2023 US sales ($167M annualized revenue)
- Only 45% of mUM patients are eligible for treatment with KIMMTRAK (unique MOA)
- KIMMTRAK captured an estimated 40% share of eligible patients within 12 months

**HEPZATO KIT approved August 14, 2023 to treat patients with liver dominant mUM**
- mUM patients with liver involvement of <50% are eligible for treatment with HEPZATO
- HEPZATO would require <20% of eligible patients to achieve similar 4 quarter growth*
- HEPZATO has no HLA genotype restrictions and will be the only FDA approved drug for 55% of all mUM patients, as well as for KIMMTRAK failure patients

**HEPZATO KIT is well positioned to capture a similar share of its TAM**
- HEPZATO is more of a complement than a competitor to KIMMTRAK for patients eligible for KIMMTRAK
- HEPZATO EAP patients have included: 1st line stand alone treatment, 1st line treatment for those intending to receive KIMMTRAK, as 2nd line treatment, and as a 3rd line palliative treatment
- NCCN Guidelines currently state “regional isolation perfusion of the liver” as a recommended treatment
- “If disease is confined to the liver, regional therapies...should be considered. Since tebentafusp-tebna response rates are low, symptomatic patients may be better palliated by liver-directed treatment first…” NCCN Guidelines Melanoma Uveal V1.2023

*Assuming a $150,000 per kit cost and 4 kits per patient
Clinical Rationale for Broad Development Effort

- **PHP treats the entire liver and is not dependent on tumor location or number of lesions.**
  - Promising ORR, DCR and PFS signals seen across multiple tumor types with CHEMOSAT in Europe and in earlier studies with IHP.

- **Liver mets are often life limiting and reduce I/O efficacy.**
  - HEPZATO is the only liver directed treatment which can repeatedly treat the whole liver.
  - Early data supports that combination with I/O agents is safe and effective.

- **Converting unresectable liver metastases into resectable.**
  - Potential for significant improvement in survival.
Strong Correlation of IHP and PHP Efficacy in mUM Patients

IHP activity in CRC and NET

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>IHP (%)</th>
<th>PHP (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>mOS</td>
<td>17.1</td>
<td>17.3</td>
</tr>
<tr>
<td>mPFS</td>
<td>7.2</td>
<td>9.6</td>
</tr>
<tr>
<td>hPFS</td>
<td>10</td>
<td>9.5</td>
</tr>
<tr>
<td>Complications</td>
<td>39.1</td>
<td>23.8</td>
</tr>
<tr>
<td>Mortality</td>
<td>5.5</td>
<td>1.8</td>
</tr>
</tbody>
</table>

Meta-analysis of 8 mUM clinical studies

<table>
<thead>
<tr>
<th>IHP in mCRC</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Van Iersel</td>
<td>ORR 50%</td>
</tr>
<tr>
<td></td>
<td>mPFS 7.4 months</td>
</tr>
<tr>
<td></td>
<td>mOS 24.8 months</td>
</tr>
<tr>
<td>Magge</td>
<td>ORR 82%</td>
</tr>
<tr>
<td></td>
<td>1-year OS rate 91%</td>
</tr>
<tr>
<td></td>
<td>2-year OS rate 72%</td>
</tr>
<tr>
<td>Rothbart</td>
<td>ORR 59%</td>
</tr>
<tr>
<td></td>
<td>mTTP 7.7 months</td>
</tr>
<tr>
<td></td>
<td>mOS 28.8 months</td>
</tr>
<tr>
<td>Bartlett</td>
<td>ORR 76%</td>
</tr>
<tr>
<td></td>
<td>DOR 8.5 months</td>
</tr>
<tr>
<td></td>
<td>mOS 16 months</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IHP in mNET</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Grover</td>
<td>ORR 50%</td>
</tr>
<tr>
<td></td>
<td>DOR 15 months</td>
</tr>
<tr>
<td></td>
<td>mhPFS 7 months</td>
</tr>
<tr>
<td></td>
<td>mOS 48 months</td>
</tr>
</tbody>
</table>

IHP, or Intrahepatic Perfusion, is an invasive surgical technique for delivering high doses of chemotherapy to the liver; procedure related mortality and morbidity prevented common usage. PHP is a minimally invasive, safer procedure which accomplishes the same goals as IHP and can be performed up to 6 times.
Chemosat Has Been Used Across Multiple Tumor Types

- CE Marked - available in ~23 centers in 4 countries
- Delcath resumed direct sales on 3/1/22
- ~1,400 commercial Chemosat kits shipped to the EU

- Strong interest to fuel additional indications driven by HCP’s
- Results from over 20 retrospective and prospective trials published by independent investigators

- NICE (UK) upgraded status from “Research” to “Special Status”
- German reimbursement based on annual hospital special request (“ZE” process)
- Broader usage pending FOCUS trial publication to support reimbursement

CHEMOSAT Used In 13 Tumor Types

~70%: Metastatic Ocular Melanoma (mUM)

Other Types Treated:
- Intrahepatic Cholangiocarcinoma (ICC)
- Hepatocellular Carcinoma (HCC)
- Metastatic Colorectal Cancer (mCRC)
- Metastatic Breast (mBreast)
- Pancreatic
- Metastatic Neuroendocrine Tumors (mNET)
- Metastatic Cutaneous Melanoma (mCM)
Rationale for Combining HEPZATO with IO Therapy

Liver Metastases Suppress IO Therapy Efficacy

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis

Liver metastases “siphon” off immunotherapy response
CHOPIN: Phase mUM 1b/2 randomized study of PHP vs PHP+IO

- N=7 in Phase 1b portion of the trial
- RP2D: IPI 1mg/kg and NIVO 3mg/kg. Well tolerated, no DLTs or deaths.
- 1CR, 6 PR and 1 PD (85.7% ORR, 100% DCR) – meta-analysis of prior IO trials has shown ORR<<10%
- As of 11/15/22 the median follow-up was 29.1 months, the median PFS was 29.1 months, and the median duration of response was 27.1 months. All patients are still alive.
- 3 of 4 patients who subsequently experienced PD continued with treatment in the form of repeated Melphalan Chemosat treatments
- Ongoing randomized Phase 2 (control is Chemosat) has recruited 50% of N=76 patients and will provide an interim analysis at N=40 patients
Market Expansion: Significant Investigator Interest

Liver Dominant Patients By Cancer Type*

U.S. Incidence

0 10,000 20,000 30,000 40,000 50,000

mOM ICC mBC mNET mPC mCRC HCC

FOCUS Trial
Extensive EU Experience
Phase 2 Data
~10 EU Cases
Limited, but High Unmet Need
IHP Efficacy Well Documented
Limited, but High Unmet Need

Combination Therapy – IO Agents

U.S. Incidence

US TAM

>$1B Per Year

*Metastatic Ocular Melanoma (mOM)
Cholangiocarcinoma (ICC)
Liver-dominant Breast Cancer (mBC)
Metastatic Neuroendocrine Tumors (mNET)
Metastatic Pancreatic Cancer (mPC)
Metastatic Colorectal Cancer (mCRC)
Hepatocellular carcinoma (HCC)
Multi-Disciplinary, Experienced Leadership Team

**GERARD MICHEL**  
Chief Executive Officer  
- 30+ yrs. pharma/medtech experience  
- C-suite roles at Vericel Corp, Biodel, & NPS  
- M.S. Microbiology, B.S. Biology & Geology from the Univ. of Rochester School of Medicine  
- M.B.A. Simon School of Business & Leadership

**JOHN PURPURA**  
Chief Operating Officer  
- Past VP and Exec Director roles of Reg. Affairs for Bracco Diagnostics  
- Held senior roles Sanofi-Aventis, Bolar Pharma, Luitpold Pharma & Eon Labs  
- M.S. Mgmt. & Policy and B.S. Chemistry and Biology at the State University of NY at Stony Brook

**VOJISLAV VUKOVIC, MD PHD**  
Chief Medical Officer  
- Oncology dev. exec, global clinical expertise  
- Former CMO at Aileron, Taiho, Synta  
- MD, Univ. of Sarajevo | MSc, PhD, Univ. of Toronto  
- Published, AACR, ASCO, ASH, ESMO member

**KEVIN MUIR**  
General Manager, Interventional Oncology  
- 20+ yrs. of medtech/bioTx sales & marketing experience.  
- Field Artillery officer in the U.S. Army  
- B.S. in Management Systems Engineering at the U.S. Military Academy at West Point

**SANDRA PENNELL**  
SVP, Finance  
- 20+ years' biotech financial oversight experience  
- Manages global financial affairs, U.S. GAAP compliance  
- Led finance at Invivyd, VP at Vericel Corp  
- MSc, Accountancy, Univ. of Illinois

**BOARD OF DIRECTORS**

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>John R. Sylvester</td>
<td>Chairman</td>
</tr>
<tr>
<td>Dr. Roger G. Stoll, Ph.D.</td>
<td>Director</td>
</tr>
<tr>
<td>Elizabeth Czerepak</td>
<td>Director</td>
</tr>
<tr>
<td>Steven Salamon</td>
<td>Director</td>
</tr>
<tr>
<td>Dr. Gil Aharon, Ph.D.</td>
<td>Director</td>
</tr>
<tr>
<td>Gerard Michel</td>
<td>CEO</td>
</tr>
</tbody>
</table>
## Capital Structure and Share Information

**Share Listing - Current**

<table>
<thead>
<tr>
<th>Share Listing</th>
<th>DCTH (NASDAQ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shares Outstanding a</td>
<td>20.3M</td>
</tr>
<tr>
<td>Cash and Cash Equivalents b</td>
<td>$14.6M</td>
</tr>
<tr>
<td>Cash from 3Q Warrant Exercises c</td>
<td>$35.0M</td>
</tr>
<tr>
<td>Warrants Outstanding d</td>
<td>15.56M</td>
</tr>
<tr>
<td>Stock Options Granted</td>
<td>2.9M</td>
</tr>
<tr>
<td>2023 Q2 Cash Burn e</td>
<td>$9.6M</td>
</tr>
<tr>
<td>Debt f</td>
<td>$9.8M</td>
</tr>
<tr>
<td>52 week Low – High g</td>
<td>$2.34 - $7.99</td>
</tr>
<tr>
<td>30d Average Daily Volume h</td>
<td>2,207,716</td>
</tr>
</tbody>
</table>

### Notes:

- **a.** As of June 30, 2023; includes 15.3M of Common plus 1.1M Preferred E & E-1, 2.9M of Preferred F-2 & 1.0M Pre-funded Warrants as converted.
- **b.** As of June 30, 2023; (10-Q filing on August 9, 2023).
- **c.** 7.78M Tranche A warrants exercised 21 days after receipt of FDA approval for HEPZATO.
- **d.** As of June 30, 2023; 3.6M warrants at a $10 exercise price, 7.78M Tranche A warrants for an aggregate exercise price $35 million exercisable until the earlier of 3/31/2026 or 21 days receipt of FDA approval for HEPZATO (now all exercised); and 4.17M Tranche B warrants for an aggregate exercise price $25 million exercisable until the earlier of 3/31/2026 or 21 days following recording at least $10 million in quarterly U.S. revenue.
- **e.** Q2 Net cash used in operating activities (increase from Q1 2023 due to pay down of accrued liabilities).
- **f.** Includes $5.0M of notes convertible at $11.98 per common share equivalent.
- **g.** Used NASDAQ closing price information starting on September 4, 2022 – September 5, 2023.
- **h.** 30-day average calculated between on August 5, 2023 – September 5, 2023.
Delcath: Investment Summary

- 4Q launch in mUM
- KIMMTRAK proving out significant commercial opportunity (~$167M run rate) with 45% of the HEPZATO TAM
- High penetration likely due to NCCN guidelines including PHP and equivalent OS as KIMMTRAK in more advance patient population
- Management team experienced in commercializing high value, specialty products
- Multiple 2023/2024 catalysts (Launch, CHOPIN data, Revenue Build)
- Potential high value follow-on indications and strategic interest creates significant upside
THANK YOU
References


References


References


